LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Strona główna・Stock List・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Closed

SectorHealthcare

14.14 -1.46

Buy Sell

Overview

Share price change

24h

Current

Min

13.96

Max

14.44

Key metrics
By Trading Economics
Income	-445K -19M
Sales	-3.2M 15M
EPS	-0.87
Profit margin	-123.636
Employees	120
EBITDA	-883K -16M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+8.56% upside

Market Stats
By TradingEconomics
Market Cap	39M 409M
Previous open	15.6
Previous close	14.14

News Sentiment

By Acuity

29%

71%

93 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

5.04 / 5.44 Support & Resistance

ENANTA PHARMACEUTICALS INC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 gru 2025, 22:02 UTC

Earnings

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10 gru 2025, 21:46 UTC

Earnings

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10 gru 2025, 23:52 UTC

Acquisitions, Mergers, Takeovers

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10 gru 2025, 23:43 UTC

Market Talk

Nikkei May Rise After Fed Rate Cut -- Market Talk

10 gru 2025, 23:36 UTC

Market Talk

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10 gru 2025, 23:20 UTC

Earnings

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10 gru 2025, 23:15 UTC

Earnings

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10 gru 2025, 22:59 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10 gru 2025, 22:45 UTC

Market Talk

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10 gru 2025, 22:40 UTC

Earnings

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 gru 2025, 22:06 UTC

Acquisitions, Mergers, Takeovers

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 gru 2025, 22:06 UTC

Earnings

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 gru 2025, 22:02 UTC

Earnings

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 gru 2025, 22:00 UTC

Earnings

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10 gru 2025, 21:53 UTC

Earnings

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 gru 2025, 21:50 UTC

Acquisitions, Mergers, Takeovers

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10 gru 2025, 21:50 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

10 gru 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

10 gru 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

10 gru 2025, 21:45 UTC

Acquisitions, Mergers, Takeovers

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 gru 2025, 21:33 UTC

Earnings

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10 gru 2025, 21:32 UTC

Earnings

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 gru 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10 gru 2025, 21:25 UTC

Earnings

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 gru 2025, 21:18 UTC

Acquisitions, Mergers, Takeovers

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10 gru 2025, 21:16 UTC

Earnings

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10 gru 2025, 21:15 UTC

Acquisitions, Mergers, Takeovers

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10 gru 2025, 21:15 UTC

Earnings

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10 gru 2025, 21:14 UTC

Earnings

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10 gru 2025, 21:14 UTC

Earnings

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Peer Comparison

Price change

ENANTA PHARMACEUTICALS INC Forecast

Price Target

By TipRanks

8.56% upside

12 Months Forecast

Average 15.6 USD 8.56%

High 20 USD

Low 9 USD

Based on 5 Wall Street analysts offering 12 month price targets forENANTA PHARMACEUTICALS INC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to ENANTA PHARMACEUTICALS INC - Dist in the past 3 months.

Technical Score

By Trading Central

5.04 / 5.44Support & Resistance

Recent bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

93 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.